Your browser is no longer supported. Please, upgrade your browser.
Settings
APRE Aprea Therapeutics, Inc. daily Stock Chart
APRE [NASD]
Aprea Therapeutics, Inc.
Index- P/E- EPS (ttm)-26.67 Insider Own1.30% Shs Outstand19.63M Perf Week2.59%
Market Cap474.26M Forward P/E- EPS next Y-1.99 Insider Trans0.00% Shs Float19.63M Perf Month-2.58%
Income- PEG- EPS next Q-0.40 Inst Own0.20% Short Float0.10% Perf Quarter-
Sales- P/S- EPS this Y-2.20% Inst Trans- Short Ratio0.16 Perf Half Y-
Book/sh-59.91 P/B- EPS next Y30.70% ROA- Target Price26.67 Perf Year-
Cash/sh3.11 P/C7.77 EPS next 5Y- ROE- 52W Range15.10 - 32.04 Perf YTD17.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-24.61% Beta-
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low60.00% ATR2.15
Employees14 Current Ratio10.90 Sales Q/Q- Oper. Margin- RSI (14)48.44 Volatility6.50% 9.36%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.84 Prev Close25.61
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume123.84K Price24.16
Recom2.70 SMA20-6.10% SMA501.23% SMA2001.23% Volume104,325 Change-5.66%
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
Nov-29-19 09:24AM  Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally? Zacks +6.92%
Nov-14-19 04:15PM  Aprea Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire +10.37%
Nov-11-19 04:40PM  RBC: 3 Stock Picks Set to Soar 30%+ TipRanks
Nov-06-19 09:15AM  Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting GlobeNewswire
Oct-11-19 05:01PM  Gates-Backed Vir Biotechnology Flops in Trading Debut Bloomberg
04:04PM  Insiders Roundup: Facebook, American Defense Systems GuruFocus.com
Oct-08-19 03:59PM  Large Amounts Of Insider Trading In Aprea Therapeutics Following IPO Benzinga -6.47%
Oct-07-19 04:15PM  Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +6.19%
Oct-03-19 11:09AM  Aprea Therapeutics' stock opens 3.1% above IPO price, then rises further MarketWatch
Oct-02-19 11:03PM  Aprea Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
Sep-30-19 10:21AM  IPO Outlook For The Week: Banks And Biotechs Benzinga
Sep-23-19 08:55AM  Aprea Therapeutics to offer 5 million shares in its IPO, priced at $14 to $16 each MarketWatch
Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.